ANUHPHRBSEAnuh Pharma LtdHighNeutral
Announced Wed, 20 May · 23:51 IST

Appointment of Scrutinizer for the 66th Annual General Meeting.

Pat NegativeEbitda Margin CompressionResults View source PDF

ANUHPHR · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reaction · full curve 14 horizons · vs prior close
-6.2%1-day move
₹81.50
prior close
₹80.81
base price
After-mkt
timing
5m10m15m30m1D2D3D4D5D7D15D1M2M3M
-3.5-3.5-4.3-4.6-6.2-6.3-6.1-6.1-6.1-7.5-2.5-3.2-1.4
Up moveDown movePending
AI summary

Anuh Pharma Ltd reported FY2026 revenue of Rs. 77,165.74 Lakhs, up 16.6% from Rs. 66,151.49 Lakhs in FY2025. However, profit after tax declined 13.3% to Rs. 4,104.61 Lakhs from Rs. 4,735.19 Lakhs. EBITDA margin compressed significantly to 8.56% from 10.64% year-over-year. The company posted negative operating cash flow of Rs. 301.16 Lakhs versus positive Rs. 3,712.47 Lakhs in the prior year. The Board recommended a dividend of Rs. 1.50 per share (30% payout) subject to shareholder approval at the AGM on 12th August 2026. Statutory auditors issued an unmodified opinion on the audited financial results.

Likely market impact

The stock may face pressure due to PAT decline, margin compression, and negative operating cash flow despite revenue growth. The clean audit opinion is a positive factor. Dividend announcement provides some support for shareholders.